RxDoctor Payments Data

Tarun Bhargava, MD

Adult Reconstructive Orthopaedic Surgery · Wichita, KSNPI 1952527442

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.5%), royalties or licence payments and travel and lodging — rather than concentrated in one kind of arrangement. Encore Medical, LP accounts for 88.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $130,652 and has fallen 65.8% since, to $44,680 in 2025.

$533,798in general payments, 2019–2025

Across 408 payments — averaging $1308.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Encore Medical, LP$474K
  • Orthalign Inc$45K
  • Innovation Technologies Inc$11K
  • Pacira Pharmaceuticals Incorporated$1K
  • Stryker$1K
  • Conformis, Inc.$223
  • plus $752 from 11 others
$2,885in research payments, 2019–2025

Across 3 payments — averaging $961.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Encore Medical, LP$3K
$260,326in ownership & investment interests, 2019–2025

Across 7 payments — averaging $37,189 each. An ownership or investment interest held by the physician or an immediate family member.

  • Midwest Surgical Alliance, LLC$260K

What the payments were for

  • Royalty or licence$179,36634%
  • Consulting fees$306,98558%
  • Speaking & faculty fees$5,6681%
  • Travel & lodging$34,3206%
  • Food & beverage$7,4591%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult reconstructive orthopaedic surgery providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$422,171
Medicare patients
633
Services billed
4,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Amoxicillin484$656
Celecoxib24$337
Clindamycin Hcl99$242
Ondansetron OdtOndansetron16$81
Cyclobenzaprine Hcl16$49
Cephalexin13$38

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →